Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total on time without troublesome dyskinesia compared with...
Neuroscience biotech Cerevel Therapeutics said data readouts for several clinical trials will come later than originally expected, and also disclosed the upcoming departure of its president, Abraham Ceesay.
BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that the first participants have been dosed in all three of the clinical trials in their Phase 3 program evaluating tavapadon in patients with Parkinson’s disease. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Tavapadon is an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes. It has been rationally designed with the goal of balancing meaningful motor control activity while minimizing the side effects typical of drugs that non-selectively stimulate dopamine.